TDP Biotherapeutics, Inc.

TDP is developing an anticancer drug that inhibits cancer and leaves normal cells unharmed. Product is ready for Pharm/Tox then Orphan IND.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Gaithersburg, MD, USA
  • Currency USD
  • Founded October 2010
  • Employees 1

Company Summary

TDP Biotherapeutics holds the exclusive license to a highly targeted anticancer drug that interferes with a protein manifested by cancer cells but not by normal cells. The synthesis, formulation, manufacturing methods, in vivo proof of concept, BA/PK are all complete. The company seeks $1.5 million to bring the product through IND enabling Pharm/Tox before initiating a first in human study in an orphan indication.

Team

  • Lisa Beth Ferstenberg, M.D.
    President, CEO

    LBF is a serial entrepreneur with 30 year history of cancer/immunology drug development and successful exit. Using resources for high level contractors, she runs TDP as virtual, focusing all investment on moving toward IND. Her depth of experience in every phase of drug development makes this feasible, and her business experience makes this cost effective. LBF teaches entrepreneurship at Hopkins/UMD and is known for creative business solutions

  • LisaBeth Ferstenberg

Advisors

  • Polsinelli Shughart, PC
    Lawyer
    Unconfirmed
    McGladrey
    Accountant
    Unconfirmed

Previous Investors

  • Dani's Foundation
    Unconfirmed
    LB Ferstenberg, M.D.
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free